Gilman Hill Asset Management LLC grew its stake in shares of Celgene Co. (NASDAQ:CELG) by 18.6% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 7,416 shares of the biopharmaceutical company’s stock after buying an additional 1,165 shares during the quarter. Gilman Hill Asset Management LLC’s holdings in Celgene were worth $686,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of CELG. Dimensional Fund Advisors LP grew its stake in shares of Celgene by 4.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,014,480 shares of the biopharmaceutical company’s stock worth $129,095,000 after buying an additional 80,990 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Celgene by 8.6% during the fourth quarter. Geode Capital Management LLC now owns 9,942,267 shares of the biopharmaceutical company’s stock worth $636,179,000 after buying an additional 787,638 shares during the last quarter. Actinver Wealth Management Inc. bought a new stake in shares of Celgene during the fourth quarter worth $2,656,000. MUFG Securities EMEA plc grew its stake in shares of Celgene by 2,360.7% during the fourth quarter. MUFG Securities EMEA plc now owns 469,200 shares of the biopharmaceutical company’s stock worth $30,071,000 after buying an additional 450,132 shares during the last quarter. Finally, Pinnacle Bank bought a new stake in shares of Celgene during the fourth quarter worth $105,000. 74.84% of the stock is currently owned by hedge funds and other institutional investors.

CELG has been the topic of a number of recent research reports. Atlantic Securities lowered shares of Celgene from an “overweight” rating to a “neutral” rating and set a $94.34 price target on the stock. in a report on Monday, April 1st. William Blair initiated coverage on shares of Q2 in a report on Monday, April 1st. They set an “outperform” rating and a $69.71 price target on the stock. BidaskClub upgraded shares of Xilinx from a “hold” rating to a “buy” rating in a report on Wednesday, July 24th. Barclays set a $24.00 price target on shares of Orion Engineered Carbons and gave the stock a “hold” rating in a report on Friday, May 3rd. Finally, Cantor Fitzgerald set a $11.00 price target on shares of TAIWAN LIPOSOME/S and gave the stock a “buy” rating in a report on Friday, April 5th. Two analysts have rated the stock with a sell rating, sixteen have issued a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $94.81.

CELG stock opened at $92.76 on Monday. The firm has a market capitalization of $65.42 billion, a price-to-earnings ratio of 12.19, a price-to-earnings-growth ratio of 0.44 and a beta of 1.45. The company has a current ratio of 2.78, a quick ratio of 2.66 and a debt-to-equity ratio of 2.42. Celgene Co. has a 12-month low of $58.59 and a 12-month high of $98.97. The firm has a fifty day moving average price of $93.87.

Celgene (NASDAQ:CELG) last released its earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.45 by $0.10. The business had revenue of $4.03 billion for the quarter, compared to analyst estimates of $4.01 billion. Celgene had a net margin of 30.10% and a return on equity of 106.69%. Celgene’s revenue for the quarter was up 13.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.05 earnings per share. Equities analysts anticipate that Celgene Co. will post 9.85 earnings per share for the current year.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Read More: What are CEFs?

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.